Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Kalaris Therapeutics, Inc. (KLRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: KLRS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20.5
1 Year Target Price $20.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -88.3% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.26M USD | Price to earnings Ratio - | 1Y Target Price 20.5 |
Price to earnings Ratio - | 1Y Target Price 20.5 | ||
Volume (30-day avg) 2 | Beta - | 52 Weeks Range 2.14 - 24.15 | Updated Date 08/12/2025 |
52 Weeks Range 2.14 - 24.15 | Updated Date 08/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.71 |
Earnings Date
Report Date 2025-08-07 | When Before Market | Estimate -0.52 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 52038779 | Price to Sales(TTM) - |
Enterprise Value 52038779 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 18702400 | Shares Floating 4289774 |
Shares Outstanding 18702400 | Shares Floating 4289774 | ||
Percent Insiders 17.19 | Percent Institutions 70.34 |
Upturn AI SWOT
Kalaris Therapeutics, Inc.
Company Overview
History and Background
Kalaris Therapeutics, Inc., formerly known as La Jolla Pharmaceutical Company, was founded in 1989. Initially focused on severe life-threatening diseases, it has evolved through acquisitions and strategic shifts, including its rebranding to Kalaris and focus on cell therapies for autoimmune diseases.
Core Business Areas
- Cell Therapy Development: Kalaris focuses on developing and commercializing cell therapies, particularly engineered mesenchymal stem cells (MSCs) to treat autoimmune diseases.
Leadership and Structure
The company is led by a management team with experience in cell therapy development and commercialization. Details on the precise organizational structure requires further research to ensure absolute accuracy and recent updates.
Top Products and Market Share
Key Offerings
- Remestemcel-L: Remestemcel-L is Kalaris's lead product candidate, an allogeneic mesenchymal stem cell (MSC) therapy. It is currently under investigation for the treatment of acute graft-versus-host disease (aGVHD). Market share data is currently difficult to ascertain with precision due to the product being under development. Competitors in the broader cell therapy space include companies developing CAR-T therapies and other MSC-based treatments (e.g., Mesoblast (MESO)).
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advances in biotechnology and increasing prevalence of autoimmune diseases and cancer. It's characterized by high innovation, regulatory complexity, and significant investment.
Positioning
Kalaris is positioned as a developer of cell therapies for autoimmune diseases. Their competitive advantage lies in their specific MSC technology and targeted therapeutic approach.
Total Addressable Market (TAM)
The global cell therapy market is projected to reach hundreds of billions USD. Kalaris is positioned to capture a share of the market addressing the Autoimmune disease therapies which are projected to reach a market of $180 billion by 2030. Kalaris's potential market capture depends on the success of clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel cell therapy platform
- Experienced management team
- Potential to address unmet medical needs in autoimmune diseases
Weaknesses
- Limited product portfolio
- Reliance on clinical trial success
- Dependence on regulatory approvals
- Relatively small company with limited resources
Opportunities
- Expanding cell therapy market
- Potential for strategic partnerships
- Acquisition of complementary technologies
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- MESO
- BMY
- NVS
Competitive Landscape
Kalaris faces competition from larger pharmaceutical companies with established cell therapy programs. Its advantage lies in its focused approach and potentially differentiated MSC technology. CLBS is much smaller and less diverse than the other companies, MESO, BMY, NVS. CLBS and MESO are more similar and have more comparable sizes.
Major Acquisitions
ARDS Biotherapeutics
- Year: 2024
- Acquisition Price (USD millions): 10
- Strategic Rationale: Expanded the company's therapeutic pipeline with an engineered MSC therapeutic candidate to treat Acute Respiratory Distress Syndrome.
Growth Trajectory and Initiatives
Historical Growth: Kalaris's historical growth is characterized by strategic pivots and acquisitions. It's focusing on cell therapy after previously concentrating on other therapeutic areas.
Future Projections: Future growth depends heavily on the success of Remestemcel-L clinical trials and regulatory approval. Analyst estimates are not broadly available due to the nature of the company. If aGVHD treatment is successful, there is growth in other Auto Immune areas, and also growth in other cell therapies
Recent Initiatives: Recent initiatives include focusing on late-stage assets and cell therapies.
Summary
Kalaris Therapeutics is a development-stage biotech company focused on cell therapies, particularly for autoimmune diseases. Its success hinges on the clinical trial success of Remestemcel-L, which could be transformative if successful. The company faces competition from larger pharma players and requires further capital to see programs to completion. The leadership team and approach to Auto Immune diseases is working well and provides strong direction. Investors should watch out for regulatory hurdles and risks associated with clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Yahoo Finance
- Other publicly available information
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share and competitor analysis are estimates based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kalaris Therapeutics, Inc.
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2020-07-30 | President, CEO & Director Mr. Andrew Oxtoby | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://kalaristx.com |
Full time employees 14 | Website https://kalaristx.com | ||
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.